# Renal Optimization Strategies Evaluation in Acute Heart Failure and Reliable Evaluation of Dyspnea in the Heart Failure Network (ROSE) Study

> **NCT01132846** · PHASE2 · COMPLETED · sponsor: **Duke University** · enrollment: 360 (actual)

## Conditions studied

- Acute Heart Failure

## Interventions

- **OTHER:** Placebo
- **DRUG:** Nesiritide
- **DRUG:** Dopamine

## Key facts

- **NCT ID:** NCT01132846
- **Lead sponsor:** Duke University
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2010-08
- **Primary completion:** 2013-05
- **Final completion:** 2013-06
- **Target enrollment:** 360 (ACTUAL)
- **Last updated:** 2014-08-21

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01132846

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01132846, "Renal Optimization Strategies Evaluation in Acute Heart Failure and Reliable Evaluation of Dyspnea in the Heart Failure Network (ROSE) Study". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT01132846. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*